News
Dystrogen Therapeutics Announces Approval of Clinical Trial Application (CTA) to Initiate a Phase 1/2 Clinical Trial of DT-DEC01 for the Treatment of Duchenne Muscular Dystrophy
Dec 20, 2023
Dystrogen Therapeutics Corp announces new publication “Safety and Efficacy of DT-DEC01 Therapy in Duchenne Muscular Dystrophy Patients: A 12 – Month Follow-Up Study After Systemic Intraosseous Administration”
Sep 17, 2023
Capstan Medical hauls in $31M to develop robotic transcatheter heart valve replacements
A startup that aims to integrate robotics with minimally invasive heart valve procedures has collected $31.4 million in venture capital funding. A startup that aims to integrate robotics with minimally invasive heart valve procedures has collected $31.4 million in venture…
Sep 8, 2023
Analyst Coverage Initiated for Medicalgorithmics with BUY rating
Sep 7, 2023
Dystrogen Therapeutics Corp Announces Presentation of Abstracts at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference
Jan 23, 2023
Conclusion of an investment agreement regarding the acquisition of new shares in the Company for a contribution of approximately PLN 220 million (PLN 44.27 per share).
Oct 1, 2022